Collectively, our findings establish RAD52 as a promising therapeutic target to overcome PARP inhibitor resistance in <i>BRCA2</i> -mutated ovarian cancer and offer mechanistic insights to inform future clinical strategies. This evidence concerns the gene BRCA2 and ovarian cancer.